Brokers Offer Predictions for BPMC Q1 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Thursday, February 13th. Leerink Partnrs analyst A. Berens expects that the biotechnology company will post earnings of ($0.77) per share for the quarter. The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.29) per share. Leerink Partnrs also issued estimates for Blueprint Medicines' Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.37) EPS.

A number of other equities research analysts also recently issued reports on BPMC. HC Wainwright restated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. StockNews.com cut Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Friday, February 14th. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 target price on the stock. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company cut their target price on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $123.83.

Blueprint Medicines Trading Up 0.3 %

Shares of NASDAQ:BPMC traded up $0.28 during midday trading on Monday, reaching $94.35. The company's stock had a trading volume of 842,019 shares, compared to its average volume of 1,035,894. The firm has a market cap of $6.03 billion, a price-to-earnings ratio of -87.36 and a beta of 0.62. The business has a 50 day moving average price of $99.53 and a 200 day moving average price of $94.40. Blueprint Medicines has a 1 year low of $80.42 and a 1 year high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds have recently modified their holdings of BPMC. GF Fund Management CO. LTD. purchased a new position in shares of Blueprint Medicines in the fourth quarter worth approximately $116,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Blueprint Medicines by 5.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,946 shares of the biotechnology company's stock worth $20,928,000 after purchasing an additional 12,035 shares in the last quarter. Woodline Partners LP raised its stake in Blueprint Medicines by 19.1% during the 4th quarter. Woodline Partners LP now owns 540,192 shares of the biotechnology company's stock valued at $47,116,000 after purchasing an additional 86,614 shares during the period. Zimmer Partners LP boosted its position in shares of Blueprint Medicines by 59.5% in the fourth quarter. Zimmer Partners LP now owns 33,650 shares of the biotechnology company's stock worth $2,935,000 after buying an additional 12,550 shares during the period. Finally, Tema Etfs LLC purchased a new position in shares of Blueprint Medicines during the fourth quarter valued at $1,960,000.

Insider Activity at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 15,161 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the sale, the director now directly owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ariel Hurley sold 1,819 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the sale, the insider now directly owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 over the last quarter. 4.21% of the stock is currently owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.